novocure-NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates

NovoCure (NVCR) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of$ 0.34. This compares to loss of $0.46 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 17.65%. A quarter ago, it was expected that this oncology drug developer would post a loss of$ 0.40 per share when it actually produced a loss of $0.31, delivering a surprise of 22.50%. Over the last four quarters, the company h ...